Resources from the same session
LBA85 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
Presenter: Benjamin Besse
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA86 - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Presenter: Jonathan Goldman
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1781MO - IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
Presenter: Stephen Liu
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1782MO - Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
Presenter: Hye Ryun Kim
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1895MO - Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
Presenter: Hidetoshi Hayashi
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1896MO - Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
Presenter: Daniel C. Christoph
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA49 - Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
Presenter: Corinne Faivre-Finn
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1236MO - A single-arm phase II study of gefitinib with concurrent thoracic radiotherapy in unresectable locally-advanced non-small cell lung cancer patients with EGFR mutation (West Japan Oncology Group 6911L)
Presenter: Junichi Shimizu
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1237MO - SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
Presenter: Sacha Rothschild
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Oliver Gautschi
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast